One test. 23 conditions.
Published literature supports digitized spiral analysis as an objective, quantitative endpoint across these neurological conditions. NeuroQuantix standardizes this evidence base into a regulatory-grade platform that delivers pre-specified endpoints for your specific indication. Each condition produces a characteristic kinematic signature that objective measurement can identify and quantify.
Built on 300+ peer-reviewed studies spanning 44 years of research. Our scoping review of 120 studies in Movement Disorders Clinical Practice maps the full evidence base.
Published Validation Data
These conditions have the deepest published evidence for digital spiral analysis endpoints, with condition-specific validation studies and quantified performance metrics.
Supported by Published Literature
Published literature supports digital spiral analysis for these conditions. NeuroQuantix captures the kinematic signatures that traditional rating scales for each condition cannot objectively measure.
Cerebellar Ataxia
SARA, ICARSCaptures dysmetria, intention tremor, and coordination deficits. Spiral Width Variability Index (SWVI) achieves ICC of 0.9 and correlates with SARA/ICARS at r = 0.7-0.8. Applicable to Friedreich ataxia, spinocerebellar ataxias (SCA), and acquired cerebellar disorders.
NIH/NINDS OverviewTardive Dyskinesia
AIMSQuantifies involuntary movement patterns affecting fine motor control. Provides continuous kinematic measurement where the Abnormal Involuntary Movement Scale (AIMS) relies on ordinal clinician ratings. Relevant for VMAT2 inhibitor and second-generation antipsychotic safety monitoring.
NIH/NINDS OverviewFunctional (Psychogenic) Tremor
Clinical assessmentKinematic signatures of functional tremor differ from organic tremor in variability, entrainment, and distractibility patterns. Spiral analysis provides objective markers that support differential diagnosis in clinical trial screening.
Huntington Disease
UHDRSCaptures chorea-related motor disruption, fine motor slowing, and coordination loss in spiral drawing. Relevant for antisense oligonucleotide and gene-silencing trials where the Unified Huntington Disease Rating Scale (UHDRS) composite may lack sensitivity to early motor changes.
NIH/NINDS OverviewWilson Disease
Unified Wilson Disease Rating ScaleTremor, dystonia, and motor coordination deficits in Wilson disease produce characteristic kinematic signatures in spiral drawing. Relevant for copper chelation and gene therapy trials targeting hepatolenticular degeneration.
NIH/NINDS OverviewMultiple Sclerosis Tremor
EDSS (motor component)Intention tremor and dysmetria in MS produce distinct spiral drawing patterns. Kinematic analysis captures the cerebellar and brainstem components of MS-related motor dysfunction that composite disability scales (EDSS) do not isolate.
NIH/NINDS OverviewFull 23-Condition Differential
NeuroQuantix generates differential likelihood profiles across all 23 conditions. Each condition has a characteristic kinematic fingerprint defined by tremor frequency, amplitude modulation, velocity profiles, and pressure dynamics.
13-18 Hz
3-5 Hz, rest + intention
8-12 Hz
Bradykinesia signature
Task-specific activation
Irregular high-frequency bursts
Combined signature
Motor slowing + rigidity
Intention tremor + ataxia
Variable frequency
Asterixis + motor slowing
Asymmetric motor recovery
Gene Therapy & Rare Disease Trials
For many neurological gene therapy indications, the global addressable population numbers in the hundreds. Traditional endpoints requiring 50-100 subjects per arm make randomized controlled trials mathematically infeasible.
The solution is not to lower the evidentiary bar. It is to use measurement tools with sufficient precision that smaller samples achieve adequate statistical power.
NeuroQuantix digital metrics, with published effect sizes of d = 1.4-3.96, achieve 80% power with as few as 6-9 subjects per arm compared to 25-65 subjects with traditional scales. This applies across ET, PD, dystonia, and rare genetic movement disorders targeted by AAV gene therapy, antisense oligonucleotides, and CRISPR-based approaches.
Sample Size Comparison
Published Digital Spiral Metrics (d = 1.7)
80% power
TETRAS / FTM (SRM 0.5)
80% power
MDS-UPDRS (SRM 0.3)
80% power
Based on published data. Haubenberger et al., 2011. DOI: 10.1002/mds.23808
Frequently Asked Questions
How does NeuroQuantix assess 23 different neurological conditions from one test?
Each neurological condition produces a characteristic kinematic signature during spiral drawing: tremor frequency bands, velocity profiles, pressure dynamics, and spatial trajectory patterns differ across conditions. NeuroQuantix applies 82 deterministic diagnostic rules to generate differential likelihood profiles rather than binary classifications. This means the platform identifies which conditions are most consistent with the observed motor patterns.
Can NeuroQuantix replace condition-specific rating scales like TETRAS, MDS-UPDRS, or SARA?
NeuroQuantix is designed to complement or replace traditional rating scales as a clinical trial endpoint. For essential tremor (TETRAS), published data shows ICC of 0.97 vs. 0.74-0.85 for the scale. For Parkinson disease (MDS-UPDRS), AUC reaches 0.862 with domain-specific metrics the composite scale cannot isolate. The regulatory pathway involves COA/DDT qualification through FDA, EMA, and other agencies.
How does digital spiral analysis support gene therapy and rare disease trials?
Gene therapy and rare disease trials face a fundamental constraint: small patient populations. Traditional scales with standardized response means of 0.3-0.5 require 50-100+ subjects per arm. Published digital spiral analysis metrics, with effect sizes of d = 1.4-3.96, demonstrate 80% power with as few as 6-9 subjects per arm. NeuroQuantix operationalizes these published metrics into a regulatory-grade endpoint that makes randomized controlled trials feasible for small populations.
What evidence supports digital spiral analysis for conditions beyond essential tremor and Parkinson disease?
The scoping review published in Movement Disorders Clinical Practice (DOI: 10.1002/mdc3.70278) systematically reviewed 120 studies across 1,407 citations spanning 44 years of digitized spiral analysis research. The review identified published validation data across essential tremor, Parkinson disease, cerebellar ataxia, dystonia, multiple sclerosis, stroke, and other conditions. NeuroQuantix addresses the standardization gaps the review identified.
Explore Further
NeuroQuantix Platform
Regulatory-grade digital endpoints backed by published effect sizes.
Published Research
Scoping review of 120 studies in Movement Disorders Clinical Practice.
Endpoint Consulting
Strategic endpoint selection and COA/DDT qualification support.
For Researchers
Validation study participation, grant support, co-authorship.
Which condition is your program targeting?
Whether your trial targets a primary indication or a rare genetic subtype, we can show you how precision digital endpoints fit your program.